IDEXX Laboratories stock initiated at Neutral by UBS with $720 target

UBS initiated coverage on IDEXX Laboratories (IDXX) with a Neutral rating and a $720 price target, noting the stock's 52.64% six-month return and current valuation above its InvestingPro Fair Value. While IDEXX recently reported strong Q2 2025 results, exceeding EPS and revenue forecasts and prompting Jefferies to raise its price target to $785 with a Buy rating, UBS suggests shares are pricing in a revenue growth deceleration to 9-10% from historical 11% CAGR, indicating that sustained double-digit growth will require greater veterinary visit volume rather than reliance on price increases.

Analysis

IDEXX Laboratories (IDXX) presents a bifurcated outlook, reflecting a classic tension between strong recent performance and forward-looking valuation concerns. The company delivered a robust second-quarter 2025, with revenue of $1.11 billion and EPS of $3.63 both exceeding forecasts, driven by 10.6% sales growth. This performance prompted Jefferies to raise its price target to $785 with a Buy rating. In contrast, UBS has initiated coverage with a Neutral rating and a $720 price target, citing the stock's substantial 52.64% gain over the past six months. UBS analysis suggests the current valuation already prices in a deceleration of revenue growth to a 9-10% range, down from the 11% historical CAGR. The firm's core thesis is that for IDEXX to return to double-digit growth, it must pivot from relying on price increases to driving higher veterinary visit volume, a key variable that currently tempers their outlook despite an attractive product pipeline.

Key Decisions for Investors

• Given the strong Q2 2025 earnings beat and Jefferies' upgraded $785 price target, momentum-focused investors might find justification for holding or initiating long positions based on the company's demonstrated operational execution.
• Conversely, value-conscious investors should consider UBS's 'Neutral' rating and analysis that the market has already priced in optimistic growth, suggesting caution is warranted after the stock's significant 52.64% six-month rally.
• The pivotal factor for future upside is the composition of revenue growth; investors should closely monitor upcoming reports for signs of accelerating veterinary visit volumes, as this will be critical to validating a growth trajectory beyond pricing power.